Dynamic contrast-enhanced MRI in oncology drug development

Area of Science:

• Oncology
• Medical Imaging
• Pharmacology

Background:

• Angiogenesis is crucial for tumor growth and metastasis.
• Developing antiangiogenesis drugs faces challenges in dosage determination and clinical effect observation.
• Imaging biomarkers show promise in accelerating drug development by providing functional, morphological, and molecular characterization.

Purpose of the Study:

• To review challenges in modern drug development.
• To explore the potential of imaging biomarkers in monitoring antiangiogenesis drug bioactivity and efficacy.
• To examine the role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in this context.

Main Methods:

• Description of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) methodology.
• Comparison of DCE-MRI with other imaging modalities for measuring hemodynamic parameters.
• Review of experience and correlative studies of DCE-MRI in antiangiogenesis cancer therapy.

Main Results:

• DCE-MRI is valuable for non-invasively measuring tumor microvasculature properties.
• The technique aids in assessing drug bioactivity and early signs of treatment efficacy.
• Correlative studies demonstrate the utility of DCE-MRI in antiangiogenesis therapy.

Conclusions:

• DCE-MRI presents a promising tool for overcoming challenges in antiangiogenesis drug development.
• Further improvements in sensitivity and reproducibility are needed for DCE-MRI.
• Future applications include imaging molecular markers for targeted therapies.